Frazier Healthcare V
Frazier Healthcare V, established in 1991, is a Seattle-based private equity firm with a focus on the healthcare sector. With over $2 billion under management, the firm invests in growth capital for healthcare companies, spanning from venture capital to growth buyouts. Frazier Healthcare V primarily invests in life science, healthcare devices and supplies, pharmaceuticals, and biotechnology sectors, demonstrating a commitment to innovation and unmet medical needs. The firm takes an active approach to portfolio management, leveraging its deep domain expertise and extensive network of industry thought leaders.
James D'Onofrio
Senior Associate
Daniel Ewnetu
Associate
Volodymyr Gulidov
Associate
Anna Hamm
Associate
Matt Hinshaw
Vice President
Michael Machak
Senior Associate
Luke Ostrander
Associate
Jack Stephenson
Associate
Jack Trunzo
Vice President
Andrew Wu
Senior Associate
Eric Yang
Associate
Jennifer Zhuang
Senior Associate
Past deals in Macau
SanReno Therapeutics
Funding Round in 2021
SanReno Therapeutics is a biotechnology company that specializes in the development, manufacturing, and commercialization of therapies for kidney diseases and related conditions. Operating primarily in the People’s Republic of China, Hong Kong, Macau, Taiwan, and Singapore, the company is dedicated to advancing research and development in this therapeutic area. Formed as a joint venture between Chinook Therapeutics, Frazier Healthcare Partners, and Pivotal bioVenture Partners China, SanReno Therapeutics aims to create innovative solutions that enhance the quality of life for patients suffering from kidney-related ailments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.